** Cancer and rare diseases drugmaker Springworks Therapeutics' SWTX.O shares surge, up about 30% to $52.70 in morning trade
** Reuters reports that German healthcare and technology group, Merck KGaA MRCG.DE is in advanced talks to acquire SWTX, according to people familiar with the matter
** If the talks are successful, a deal could be signed in the coming weeks, according to Reuters' sources
** Both Springworks and Merck declined to comment
** SWTX stock has risen 12% in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。